Ivosidenib for the treatment of IDH1-mutant glioma, grades 2–4: Tolerability, predictors of response, and outcomes

In this large cohort of IDHm glioma patients, ivosidenib was well tolerated. Our results support the use of IDHi therapy in patients with grade 2 or 3 astrocytoma or oligodendroglioma and highlight limited effectiveness in patients with enhancing disease.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Advances
Published
2024-12-19
DOI
https://doi.org/10.1093/noajnl/vdae227
Citations
9
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
3.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ivosidenib for the treatment of IDH1-mutant glioma, grades 2–4: Tolerability, predictors of response, and outcomes

L. Nicolas Gonzalez Castro, Julie J. Miller, Daniel P. Cahill, Thomas F. Flood et al.
9 citations
Neuro-Oncology Advances
Glioma Diagnosis and Treatment
3.94
article

Ivosidenib for the treatment of IDH1-mutant glioma, grades 2–4: Tolerability, predictors of response, and outcomes

L. Nicolas Gonzalez Castro, Julie J. Miller, Daniel P. Cahill, Thomas F. Flood, Patrick Y. Wen, Samuel K. McBrayer, Isabel Arrillaga‐Romany, Gilbert Youssef, Matthew N. DeSalvo, Zhou Lan, Diana D. Shi, Eudocia Q. Lee, Elmira Hassanzadeh, Vihang Nakhate, Wenya Linda Bi, Ian Pan, Jörg Dietrich, J. Lauer, Rifaquat Rahman, Ugonma Nnenna Chukwueke, Justin T. Jordan, David A. Reardon, Raymond Y. Huang, Tracy T. Batchelor, Lakshmi Nayak, Tyler Lanman, Juan Pablo Ospina, Christopher A. Potter, Deborah Forst, Elizabeth R. Gerstner, Min Lang, Albert Jiao, Natalie Stec
article en
9 citations

Abstract

In this large cohort of IDHm glioma patients, ivosidenib was well tolerated. Our results support the use of IDHi therapy in patients with grade 2 or 3 astrocytoma or oligodendroglioma and highlight limited effectiveness in patients with enhancing disease.

Neuro-Oncology AdvancesVol. 7(1)
Brigham and Women's Hospital (US), Children's Medical Center (US), Harvard University (US), Massachusetts General Hospital (US), Southwestern Medical Center (US), Center for Neuro-Oncology (US), Dana-Farber Cancer Institute (US), The University of Texas Southwestern Medical Center (US)
Brigham and Women's Hospital, Massachusetts General Hospital, University of Texas Southwestern Medical Center
Good health and well-being
Openalex Percentile: Top 6%
Glioma Diagnosis and Treatment
3.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.